Skezan, the dunce cap stays on the shelf because this is a good question to ask, so let's get to it.
What happens when the ORR substantially exceeds 6.3 percent in a CCR5-selected MSS mCRC population where no ICI has previously worked depends on which pathway the data supports at the moment it is disclosed.
The most direct route is accelerated approval under 21 CFR 601.41, which allows the FDA to approve a biologic based on a surrogate endpoint or intermediate clinical endpoint reasonably likely to predict clinical benefit, rather than waiting for final overall survival data. In an MSS mCRC population where the historical ORR on TAS-102 plus bevacizumab alone is 6.3 percent, a confirmed ORR of even 20 to 25 percent in a biomarker-selected population would represent a clinically meaningful and statistically significant improvement over the existing standard of care. The FDA has granted accelerated approval on smaller signals in populations with greater unmet need. MSS mCRC is one of the most treatment-refractory solid tumor contexts in oncology, which means the unmet need threshold is well documented and does not require additional justification.
Under accelerated approval, a confirmatory trial would be required to verify the clinical benefit, specifically overall survival improvement, in a randomized controlled trial comparing the leronlimab combination to TAS-102 plus bevacizumab alone. That confirmatory trial would run in parallel with the commercial launch rather than before it, meaning patients gain access to the drug while the confirmatory evidence is being generated. This is the pathway pembrolizumab used in multiple indications before converting accelerated approvals to full approvals following confirmatory trial results.
The Breakthrough Therapy Designation application Dr. Lalezari described submitting to the FDA in late summer 2026, based on the data package accumulated through that cutoff, is the mechanism that accelerates the review clock before the formal BLA is filed. BTD triggers rolling review, intensive FDA guidance, and organizational commitment from the agency to work collaboratively with the sponsor. A BTD in hand before the ASCO GI January 2027 confirmed ORR disclosure means the FDA has already acknowledged the preliminary data as showing substantial improvement over existing therapy in a serious condition.
The commercial consequence of an approval in MSS mCRC is the opening of the partnership negotiation in its final form rather than its preliminary form. The label architecture question, broad class authorization across checkpoint inhibitors generically versus narrow single-partner authorization, gets resolved in the BLA review process. The counterparties whose decision calculus depends on knowing whether they are acquiring exclusive combination rights or competing in an open combination landscape make their final offers once the label terms are visible.
The ticker tape parade happens on a different timeline than the approval itself, and for a different audience than the investment community. It happens when the first MSS mCRC patient who would have had a 6.3 percent chance of meaningful tumor response on the existing standard of care achieves a complete response instead, and their physician files that outcome in a case report, and Dr. Kasi presents it at a conference, and the field begins to reorganize around the upstream gate in the way independent laboratories have been documenting for the past six months from every direction simultaneously.
That is what substantially exceeding 6.3 percent actually means in human terms. The regulatory sequence is the mechanism. The patients are the point.
What happens when the ORR substantially exceeds 6.3 percent in a CCR5-selected MSS mCRC population where no ICI has previously worked depends on which pathway the data supports at the moment it is disclosed.
The most direct route is accelerated approval under 21 CFR 601.41, which allows the FDA to approve a biologic based on a surrogate endpoint or intermediate clinical endpoint reasonably likely to predict clinical benefit, rather than waiting for final overall survival data. In an MSS mCRC population where the historical ORR on TAS-102 plus bevacizumab alone is 6.3 percent, a confirmed ORR of even 20 to 25 percent in a biomarker-selected population would represent a clinically meaningful and statistically significant improvement over the existing standard of care. The FDA has granted accelerated approval on smaller signals in populations with greater unmet need. MSS mCRC is one of the most treatment-refractory solid tumor contexts in oncology, which means the unmet need threshold is well documented and does not require additional justification.
Under accelerated approval, a confirmatory trial would be required to verify the clinical benefit, specifically overall survival improvement, in a randomized controlled trial comparing the leronlimab combination to TAS-102 plus bevacizumab alone. That confirmatory trial would run in parallel with the commercial launch rather than before it, meaning patients gain access to the drug while the confirmatory evidence is being generated. This is the pathway pembrolizumab used in multiple indications before converting accelerated approvals to full approvals following confirmatory trial results.
The Breakthrough Therapy Designation application Dr. Lalezari described submitting to the FDA in late summer 2026, based on the data package accumulated through that cutoff, is the mechanism that accelerates the review clock before the formal BLA is filed. BTD triggers rolling review, intensive FDA guidance, and organizational commitment from the agency to work collaboratively with the sponsor. A BTD in hand before the ASCO GI January 2027 confirmed ORR disclosure means the FDA has already acknowledged the preliminary data as showing substantial improvement over existing therapy in a serious condition.
The commercial consequence of an approval in MSS mCRC is the opening of the partnership negotiation in its final form rather than its preliminary form. The label architecture question, broad class authorization across checkpoint inhibitors generically versus narrow single-partner authorization, gets resolved in the BLA review process. The counterparties whose decision calculus depends on knowing whether they are acquiring exclusive combination rights or competing in an open combination landscape make their final offers once the label terms are visible.
The ticker tape parade happens on a different timeline than the approval itself, and for a different audience than the investment community. It happens when the first MSS mCRC patient who would have had a 6.3 percent chance of meaningful tumor response on the existing standard of care achieves a complete response instead, and their physician files that outcome in a case report, and Dr. Kasi presents it at a conference, and the field begins to reorganize around the upstream gate in the way independent laboratories have been documenting for the past six months from every direction simultaneously.
That is what substantially exceeding 6.3 percent actually means in human terms. The regulatory sequence is the mechanism. The patients are the point.
12
